Speculation On Baxter Division Picks Up Steam
The company reported in October that it was reviewing its portfolio and would offer more details on its future plans in January. Wells Fargo analysts expect Baxter to split its fast-growing connected care business from its lower-margin hospital-based therapeutics products.
You may also be interested in...
Bob White, president of Medtronic’s medical surgical portfolio spoke to Medtech Insight about how the company develops innovative products like the Hugo robot, recent deals that carved out businesses, and the biggest opportunities for future growth and innovation.
Johnson & Johnson plans to buy Abiomed for $380 per share – about $16.6bn in total – plus up to $35 per share in potential commercial and clinical milestone-contingent payments. Abiomed is the clear leader in percutaneous circulatory support technology, but would benefit from J&J's reach and resources while complementing J&J's Biosense Webster electrophysiology business.
Medtronic announced plans to spin off its patient monitoring and respiratory interventions businesses, which currently provide revenues of over $2bn a year. The company previously signaled plans to make significant changes to its business portfolio.